- Home
- XP vs ROIV Comparison
XP vs ROIV Comparison
Compare XP & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XP | ROIV |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Cayman Islands | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 14.1B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | XP | ROIV |
|---|---|---|
| Price | $16.42 | $21.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $22.80 | ★ $24.31 |
| AVG Volume (30 Days) | 6.2M | ★ 8.2M |
| Earning Date | 02-17-2026 | 02-09-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 18.53 | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $3,229,174,949.00 | $20,329,000.00 |
| Revenue This Year | $17.10 | N/A |
| Revenue Next Year | $12.69 | $741.42 |
| P/E Ratio | $9.28 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $10.82 | $8.73 |
| 52 Week High | $20.64 | $23.47 |
Technical Indicators
Market Signals| Indicator | XP | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 53.08 |
| Support Level | $16.25 | $21.36 |
| Resistance Level | $16.69 | $22.72 |
| Average True Range (ATR) | 0.41 | 0.80 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 31.53 | 45.71 |
Price Performance
Historical ComparisonAbout XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.